12:00 AM
Jun 22, 2015
 |  BioCentury  |  Finance

Build-to-buy basket

GSK, Avalon Ventures double their build-to-buy portfolio to six start-ups

GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) and Avalon Ventures doubled the number of build-to-buys in their deal to six, including the first build-to-buy that is homegrown by the VC.

The newest cohort of companies includes Adrenergics Inc., CadheRx Therapeutics Inc. and Calporta Therapeutics Inc.

CadheRx and Calporta both have roots in academia. Calporta is developing small molecule agonists of mucolipin 1 (TRPML1; MCOLN1)...

Read the full 335 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >